27/03/2025

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

27/03/2025

Mar 27, 2025, 08:26 | Insight
Aakash Desai: Oncology dealmakers seek multi-indication therapies
Aakash Desai, Associate Director of Phase 1 and Precision Oncology Program at UAB O’Neal Comprehensive…
Mar 27, 2025, 08:09 | Career
Manchester Cancer Research Centre is hiring Head of Strategic Partnerships and Operations
Manchester Cancer Research Centre shared a post on LinkedIn: "We're hiring for a Head of…
Mar 27, 2025, 08:07 | Immune Oncology
Immunotherapy for Rectal Cancer: Types, Success Rate, Side Effects and More
Immunotherapy has emerged as a promising treatment option for rectal cancer, particularly in advanced and microsatellite instability-high (MSI-H)…
Mar 27, 2025, 08:00 | Blog
OHMX.bio joins BRECISE to revolutionize prostate and bladder cancer diagnostics
OHMX.bio shared a post on LinkedIn: "OHMX.bio joins BRECISE to revolutionize cancer diagnostics OHMX.bio is…
Mar 27, 2025, 07:45 | Career
Join the Care Wheels Program: Medicaid Cancer Foundation
Medicaid Cancer Foundation shared a post on X: "We’ve heard so many wonderful stories from…
Mar 27, 2025, 07:40 | Blog
Peter Pisters: An exceptional day at ACHE Congress
Peter Pisters, President of MD Anderson Cancer Center, shared a post on LinkedIn: "Reflecting on…
Mar 27, 2025, 07:40 | Blog
Issue four of The Christie International Fellowship Program Newsletter is now available - Manchester Cancer Research Centre
Manchester Cancer Research Centre shared a post on LinkedIn: "Issue four of The Christie International…
Mar 27, 2025, 07:38 | Drugs
Tucatinib (Tukysa): What patients need to know?
Tucatinib (brand name Tukysa) is a targeted cancer drug used to treat HER2-positive metastatic breast…
Mar 27, 2025, 07:26 | Insight
Bobby Koneru: Three Randomized Controlled Trials (RCTs) for LDRT in Knee Osteoarthritis
Bobby Koneru, President and Radiation Oncologist at POG and Affiliate Faculty at Loyola University Chicago…
Mar 27, 2025, 07:24 | Drugs
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis - Mount Sinai Department of Medicine
Mount Sinai Department of Medicine shared a post on LinkedIn: "John Mascarenhas, MD, discusses his…
All: 103 Posts: 81 - 90
Special Coverage